Dori Thomas-Karyat

dori-2

Synthis

2018

Technologies

Pharmaceutical Drug

Therapeutic

Indication

Fibrosis

Oncology

Executive Summary

View/Download

We are developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.

Newsletter Signup

Corporate Supporters